Table 1 Baseline clinical characteristics of the PF group and the DP group
Variable | PF group(N = 41) n% | DP group(N = 45) n% | P-value |
|---|---|---|---|
Gender | Â | Â | Â |
Male | 29(70.7) | 31(68.9) | 0.853 |
Female | 12(29.3) | 14(31.1) | Â |
Age (years) | Â | Â | Â |
Median (range) | 59(45–69) | 58(40–73) |  |
< 60 | 25(61.0) | 27(60.0) | 0.926 |
≥ 60 | 16(39.0) | 18(40.0) |  |
KPS | Â | Â | Â |
90 | 33(85.0) | 39(86.7) | 0.370 |
80 | 8(19.5) | 5(11.1) | Â |
70 | 0(0) | 1(2.2) | Â |
BMI (kg/m²) |  |  |  |
Median (range) | 21.5(15.7–30.8) | 21.3(17.1–27.5) |  |
< 18.5 | 6(14.6) | 4(8.9) | 0.508 |
≥ 18.5 | 35(85.4) | 41(91.1) |  |
CCI | Â | Â | Â |
0 | 31(75.6) | 31(68.9) | 0.716 |
1 | 10(24.4) | 13(28.9) | Â |
3 | 0(0) | 1(2.2) | Â |
Smoking index | Â | Â | Â |
0 | 15(36.6) | 20(44.4) | 0.755 |
> 0, ≤ 400 | 10(24.4) | 10(22.2) |  |
> 400 | 16(39.0) | 15(33.3) |  |
Drinking | Â | Â | Â |
No | 28(68.3) | 30(66.7) | 0.872 |
Yes | 13(31.7) | 15(33.3) | Â |
Tumour location | Â | Â | Â |
Cervical | 7(17.1) | 5(11.1) | 0.729 |
Upper thoracic | 13(31.7) | 19(42.2) | Â |
Middle thoracic | 16(39.0) | 15(33.3) | Â |
Lower thoracic | 3(7.3) | 2(4.4) | Â |
Multiple primary | 2(4.9) | 4(8.9) | Â |
Tumour length (mm) | Â | Â | Â |
Median (range) | 55(10–150) | 47(20–96) |  |
T stage* | Â | Â | Â |
T1 | 1(2.4) | 0(0) | 0.191 |
T2 | 4(9.8) | 10(22.2) | Â |
T3 | 25(61.0) | 28(62.2) | Â |
T4 | 11(26.8) | 7(15.6) | Â |
N stage* | Â | Â | Â |
N0 | 2(4.9) | 3(6.7) | 1.000 |
N1 | 39(95.1) | 42(93.3) | Â |
M stage* | Â | Â | Â |
M0 | 30(73.2) | 30(66.7) | 0.512 |
M1a | 11(26.8) | 15(33.3) | Â |
TNM stage* | Â | Â | Â |
IIA, IIB | 4(9.8) | 9(20.0) | 0.236 |
III | 26(63.4) | 21(46.7) | Â |
IVA | 11(26.8) | 15(33.3) | Â |